Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology
+$1.11 today
- Market cap
- $4.45B
- Beta
- 0.30
- P/E (TTM)
- -21.9
- EPS (TTM)
- -$1.64
Volume 0.87M
Average 1.32M
EWTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Edgewise Therapeutics, Inc.NASDAQ: EWTX
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation growth accelerates
Q3 FY2026 stock-based compensation of $8.56M rose 5.9% year over year, ahead of the -94.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 8.5% from the prior quarter. Over 3 fiscal years it compounded at +47.1% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +5.9% holds above the trailing-twelve-month pace of -94.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 34.75M USD
- Year-over-year change
- +40.6%
- 4-year CAGR
- +67.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.75M | +40.6% |
| FY2024 | 2024-12-31 | 24.71M | +40.7% |
| FY2023 | 2023-12-31 | 17.56M | +60.7% |
| FY2022 | 2022-12-31 | 10.92M | +148.0% |
| FY2021 | 2021-12-31 | 4.4M | — |
Stock-Based Compensation vs competitors
How EWTX compares with its peers on the latest reported figures
- EWTX's LTM Sep 2026 stock-based compensation of $1.76M is the smallest of the 10 companies compared; the peer median is $26.2M.
- Its year-over-year change of -94.6% is the lowest of 10, against a peer median of -8.1%.
- Over three fiscal years its annual growth of +47.1% compares with a peer median of +25.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.98B | +32410.1% | +56.9% | — | |
| LTM Mar 2026 | $111.37M | -39.8% | -19.1% | 5.1% | |
| LTM Jun 2026 | $84.66M | +15.0% | -12.3% | 8.4% | |
| LTM Jun 2026 | $39.28M | -8.1% | +44.6% | — | |
| LTM Mar 2026 | $26.2M | -9.4% | +12.2% | 81.7% | |
| LTM Mar 2026 | $19.27M | -0.0% | +25.6% | 335.8% | |
| LTM Mar 2026 | $18.73M | +52.9% | +30.9% | — | |
| LTM Mar 2026 | $10.03M | -22.0% | +30.6% | — | |
| LTM Mar 2026 | $7.15M | -15.9% | +1.9% | — | |
| LTM Sep 2026 | $1.76M | -94.6% | +47.1% | — | |
| Peer median (excluding EWTX) | $26.2M | -8.1% | +25.6% | 45.0% | |
Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Depreciation & Amortization | 272K | 538K | 1.73M | 2.29M | 2.27M |
| Deferred Income Tax | (2.29M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.4M | 10.92M | 17.56M | 24.71M | 34.75M |
| Change in Working Capital | 4.63M | 4.09M | (1.56M) | 10.33M | (5.37M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.65M | 47K | (92K) | 1.74M | 272K |
| Other Working Capital | 1.98M | 4.04M | (1.47M) | 8.59M | (5.65M) |
| Other Non-Cash Items | 2.29M | (543K) | (9.52M) | (12.55M) | (7.67M) |
| Operating Cash Flow | (33.51M) | (52.64M) | (91.95M) | (109.03M) | (143.82M) |
| Capital Expenditures | (668K) | (5.55M) | (5.75M) | (1.31M) | (256K) |
| Acquisitions (Net) | 241.56K | 65.03K | 0 | 0 | 0 |
| Purchases of Investments | (288.2M) | (292.39M) | (255.87M) | (477.06M) | (527.23M) |
| Sales of Investments | 46.64M | 227.36M | 364.5M | 293.71M | 494.69M |
| Other Investing Activities | (241.56K) | (65.03K) | 0 | 0 | 0 |
| Investing Cash Flow | (242.23M) | (70.58M) | 102.89M | (184.66M) | (32.79M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 186.15M | 129.17M | 52.62M | 239.15M | 196.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 236K | 474K | 548K | 10.11M | 0 |
| Financing Cash Flow | 186.38M | 129.64M | 53.17M | 249.25M | 196.09M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (89.35M) | 6.43M | 64.1M | (44.43M) | 19.48M |
| Free Cash Flow | (34.18M) | (58.18M) | (97.69M) | (110.34M) | (143.82M) |
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Intrinsic Alpha fair value
Locked
Current Price
$41.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.